Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, announced that CEO Nick Colangelo will present at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 9:00 a.m. Eastern Time. A live webcast of the presentation will be available on the company’s Investor Relations website. Vericel markets two key cell therapy products: MACI®, for knee cartilage repair, and Epicel®, a permanent skin replacement for severe burns. The company also has exclusive rights to NexoBrid®, a biological product for burn debridement.

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Ladenburg Thalmann Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Tuesday, July 13, 2021, at 9:00 a.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

When will Vericel present at the Ladenburg Thalmann Healthcare Conference?

Vericel will present on July 13, 2021, at 9:00 a.m. Eastern Time.

Where can I watch the Vericel conference presentation?

The presentation will be available as a live webcast on Vericel's Investor Relations website.

What products does Vericel Corporation offer?

Vericel offers MACI® for knee cartilage repair and Epicel® for severe burn treatment.

What is NexoBrid® and its relevance to Vericel?

NexoBrid® is a registration-stage biological product for debridement of severe thermal burns, for which Vericel holds exclusive North American rights.

Who is presenting for Vericel at the conference?

Nick Colangelo, President and CEO of Vericel, will be presenting.